Amgen says that the final Phase III data on Vectibix for colorectal cancer demonstrated prolonged progression-free survival compared to best supportive care. "Medical advances in the treatment of first- and second-line colorectal cancer have improved survival rates; however, most patients develop resistance to these therapies, creating the need for an active agent to treat patients with advanced disease," said Professor Eric Van Cutsem, M.D., Ph.D., lead author of the manuscript. "Final results from the first large randomized trial of its kind show that Vectibix provides a benefit in this heavily pre-treated patient population."
- check out the release on the final data